Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Cipla: Waiting for Omeprazole exports - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Jul 26, 2001

    Cipla: Waiting for Omeprazole exports

    Cipla has declared a growth of 14% in net profit and a 23% growth in sales for 1QFY01. While sales growth is more or less in line with our expectations, the net profit growth is below expectations. Sales growth appears on the back of healthy increase in export sales. However, margins in the export business seem to have dropped, particularly because of low margin anti-AIDS exports. Operating margins have dipped by 100 basis points.

    (Rs m) 1QFY01 1QFY02 Change FY01
    Sales 2,418 2,979 23.2% 10,477
    Other Income 76 61 -19.3% 396
    Expenditure 1,929 2,406 24.7% 8,319
    Operating Profit (EBDIT) 489 573 17.3% 2,158
    Operating Profit Margin (%) 20.2% 19.2%   20.6%
    Interest 4 3 -37.5% 9
    Depreciation 38 48 26.7% 155
    Profit before Tax 523 584 11.7% 2,390
    Other Adjustments - -    
    Tax 135 140 3.7% 605
    Profit after Tax/(Loss) 388 444 14.5% 1,785
    Net profit margin (%) 16.0% 14.9%   17.0%
    No. of Shares (eoy) (m) 60.0 60.0   60.0
    Diluted Earnings per share 25.9 29.6   29.7
    P/E (at current price) 36   36

    The uncertainty prevailing over the export of Omeprazole by Cipla to Andrx has further intensified. Omeprazole export is considered to be a key earning opportunity for the company. Cipla has an arrangement to supply Omeprazole (bulk drug) to Andrx. Andrx in turn claims to have a six month marketing exclusivity for the drug. However, the issue is caught in a long legal tangle. Recently, the US FDA granted two more patents to AAI Pharma which could further intensify the ongoing legal battle and consequently, further delay the launch of the generic drug. The markets would be closing watching developments on the Omeprazole front in the coming months.

    The company recently launched CFC-free anti-asthma inhalers, which is expected to find a huge export market, particularly in Europe. It has also ramped its research activities in its key anti-asthma therapeutic segment. Besides, with several exclusive tie-ups for generic supply and commencement of Omeprazole plant, the company is all set to tap the vast US generic market.

    Further, though the opening up of the African market for anti-AIDS market has provided a big export opportunity for Cipla, the profitability from same is unascertainable at this point of time. Lot of other companies (including Glaxo, original patent holder) have also offered to supply the drug at concessional rates to African markets.

    We maintain a net profit growth of 44% for FY02. However, we have not factored in earnings growth for Omeprazole exports due to prevailing uncertainty. At the current market price of Rs 1074, the stock trades at 25x our expected earnings for FY02. The developments on the Omeprazole front and the exports of CFC-free inhalers are expected to drive valuations of the company in near future.



    Equitymaster requests your view! Post a comment on "Cipla: Waiting for Omeprazole exports ". Click here!


    More Views on News

    Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

    Mar 8, 2017

    Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

    Sep 19, 2016

    Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    More Views on News

    Most Popular

    This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

    Aug 17, 2017

    A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

    Aug 16, 2017

    The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 23, 2017 01:25 PM



    Compare Company With Charts